ReviewBritish journal of pharmacology2017
Relaxin and insulin-like peptide 3 in the musculoskeletal system: from bench to bedside.
Review in British journal of pharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Diagnosis and treatment of acute inflammatory sacroiliitis in pregnant or post-partum women: a systematic review of the current literature.Musculoskeletal surgery · 2024Pooled it
- Article
- Influence of Overweight and Obesity on Bone Remodeling during Pregnancy.Research square · 2025Article
- Retrospective Analysis of Balance Parameters in Pregnant Women: A Sub-Analysis of a Randomized Controlled Trial.Journal of clinical medicine · 2025Article
- Integrated Phenotypic and Transcriptomic Analyses of Osteoporosis in Type 2 Diabetic Mice.International journal of medical sciences · 2025Article
- Imaging of Sacroiliac Pain: The Current State-of-the-Art.Journal of personalized medicine · 2024Review
- Effects of pregnancy and lactation on muscle-tendon morphology.Journal of anatomy · 2023Article
- Relaxin treatment stimulates the differentiation of mesenchymal stem cells into osteoblasts.Journal of dental sciences · 2023Article
- Clinical characteristics, treatment and outcomes of acute postpartum inflammatory sacroiliitis: a retrospective study.Archives of gynecology and obstetrics · 2022Article
- Relaxin-2 during pregnancy according to glycemia, continence status, and pelvic floor muscle function.International urogynecology journal · 2022Article
- The Relationship Between Bone and Reproductive Hormones Beyond Estrogens and Androgens.Endocrine reviews · 2021Review
- Relaxin 2 carried by magnetically directed liposomes accelerates rat midpalatal suture expansion and subsequent new bone formation.Bone reports · 2019Article
- Potential therapeutic use of relaxin in accelerating closure of cranial bone defects in mice.Physiological reports · 2019Article
- Different Clinical Presentations and Management in Complete Androgen Insensitivity Syndrome (CAIS).International journal of environmental research and public health · 2019Review
- Protective Role of Testicular Hormone INSL3 From Atrophy and Weakness in Skeletal Muscle.Frontiers in endocrinology · 2018Article
- Relaxin and insulin-like peptide 3 in the musculoskeletal system: from bench to bedside.British journal of pharmacology · 2017Review
- Synthetic non-peptide low molecular weight agonists of the relaxin receptor 1.British journal of pharmacology · 2017Review
- Recent progress in the understanding of relaxin family peptides and their receptors.British journal of pharmacology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Skeletal muscles and bones form a joined functional unit sharing a complex mechanical, biochemical and hormonal crosstalk. A number of factors, including sex hormones, physiologically regulate the musculoskeletal system. Striking gender differences in muscle and bone mass, and function are mainly caused by distinct actions exerted by oestrogens and androgens. However, relaxin and relaxin-related peptides, such as insulin-like peptide 3 (INSL3), might contribute to these sex-associated differences in physiological and pathological conditions (such as osteoporosis and sarcopenia). Relaxin is a 'pregnancy' hormone, but it is also produced from the prostate gland, and has recently attracted attention as a potential drug for cardiovascular disorders and fibrosis. In contrast, INSL3 is a male-specific hormone produced by the Leydig cells of the testis with a fundamental role in testicular descent during fetal life. Recent evidence suggests that both hormones have interesting roles in the musculoskeletal system. Relaxin and INSL3, by finely tuning bone formation and resorption, are involved in bone remodelling processes, and relaxin contributes to the healing of injured ligaments and promotes skeletal muscle regeneration. Here, we review the most recent findings on the effects of relaxin and INSL3 on skeletal muscle and the cell components of bone. In the light of the experimental evidence available and animal models, their clinical implications are also discussed. LINKED ARTICLES: This article is part of a themed section on Recent Progress in the Understanding of Relaxin Family Peptides and their Receptors. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v174.10/issuetoc.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.